{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:19:28Z","timestamp":1790011168232,"version":"4.0.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,8,29]],"date-time":"2017-08-29T00:00:00Z","timestamp":1503964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2017,8,29]],"date-time":"2017-08-29T00:00:00Z","timestamp":1503964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004263","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado do Rio Grande do Sul","doi-asserted-by":"publisher","award":["PPSUS 1210-2551\/13-1"],"award-info":[{"award-number":["PPSUS 1210-2551\/13-1"]}],"id":[{"id":"10.13039\/501100004263","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004263","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado do Rio Grande do Sul","doi-asserted-by":"publisher","award":["PRONEX 16\/2551"],"award-info":[{"award-number":["PRONEX 16\/2551"]}],"id":[{"id":"10.13039\/501100004263","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["Universal 458139\/2014-9"],"award-info":[{"award-number":["Universal 458139\/2014-9"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s10637-017-0503-7","type":"journal-article","created":{"date-parts":[[2017,8,29]],"date-time":"2017-08-29T04:17:07Z","timestamp":1503980227000},"page":"323-331","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Vinblastine and antihelmintic mebendazole potentiate temozolomide in resistant gliomas"],"prefix":"10.1007","volume":"36","author":[{"given":"Franciele Cristina","family":"Kipper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew Oliveira","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 Luis","family":"Marc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gl\u00e1ucia","family":"Confortin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusto Valad\u00e3o","family":"Junqueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliseu Paglioli","family":"Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4077-6316","authenticated-orcid":false,"given":"Guido","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,29]]},"reference":[{"issue":"6","key":"503_CR1","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.molmed.2011.01.011","volume":"17","author":"RY Bai","year":"2011","unstructured":"Bai RY, Staedtke V, Riggins GJ (2011) Molecular targeting of glioblastoma: drug discovery and therapies. Trends Mol Med 17(6):301\u2013312. https:\/\/doi.org\/10.1016\/j.molmed.2011.01.011","journal-title":"Trends Mol Med"},{"issue":"10","key":"503_CR2","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1517\/13543784.2015.1048332","volume":"24","author":"JH Kang","year":"2015","unstructured":"Kang JH, Adamson C (2015) Novel chemotherapeutics and other therapies for treating high-grade glioma. Expert Opin Investig Drugs 24(10):1361\u20131379. https:\/\/doi.org\/10.1517\/13543784.2015.1048332","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"503_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3978\/j.issn.2305-5839.2014.10.06","volume":"3","author":"I Veliz","year":"2015","unstructured":"Veliz I, Loo Y, Castillo O, Karachaliou N, Nigro O, Rosell R (2015) Advances and challenges in the molecular biology and treatment of glioblastoma-is there any hope for the future? Ann Transl Med 3(1):7. https:\/\/doi.org\/10.3978\/j.issn.2305-5839.2014.10.06","journal-title":"Ann Transl Med"},{"key":"503_CR4","doi-asserted-by":"publisher","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for R, Treatment of Cancer Brain T, Radiotherapy G, National Cancer Institute of Canada Clinical Trials G (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (10):987\u2013996. https:\/\/doi.org\/10.1056\/NEJMoa043330","DOI":"10.1056\/NEJMoa043330"},{"issue":"5","key":"503_CR5","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1002\/1097-0142(197505)35:5<1398::AID-CNCR2820350524>3.0.CO;2-C","volume":"35","author":"PH Gutin","year":"1975","unstructured":"Gutin PH, Wilson CB, Kumar AR, Boldrey EB, Levin V, Powell M, Enot KJ (1975) Phase II study of procarbazine, CCNU, and vincristine combination chemotherapy in the treatment of malignant brain tumors. Cancer 35(5):1398\u20131404","journal-title":"Cancer"},{"issue":"14","key":"503_CR6","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1056\/NEJMoa1500925","volume":"374","author":"JC Buckner","year":"2016","unstructured":"Buckner JC, Shaw EG, Pugh SL, Chakravarti A, Gilbert MR, Barger GR, Coons S, Ricci P, Bullard D, Brown PD, Stelzer K, Brachman D, Suh JH, Schultz CJ, Bahary JP, Fisher BJ, Kim H, Murtha AD, Bell EH, Won M, Mehta MP, Curran WJ Jr (2016) Radiation plus Procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med 374(14):1344\u20131355. https:\/\/doi.org\/10.1056\/NEJMoa1500925","journal-title":"N Engl J Med"},{"issue":"3","key":"503_CR7","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1200\/JCO.2012.43.2674","volume":"31","author":"G Cairncross","year":"2013","unstructured":"Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, Fink K, Souhami L, Laperriere N, Curran W, Mehta M (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 31(3):337\u2013343. https:\/\/doi.org\/10.1200\/JCO.2012.43.2674","journal-title":"J Clin Oncol"},{"issue":"3","key":"503_CR8","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1200\/JCO.2012.43.2229","volume":"31","author":"MJ van den Bent","year":"2013","unstructured":"van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Enting RH, French PJ, Dinjens WN, Vecht CJ, Allgeier A, Lacombe D, Gorlia T, Hoang-Xuan K (2013) Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 31(3):344\u2013350. https:\/\/doi.org\/10.1200\/JCO.2012.43.2229","journal-title":"J Clin Oncol"},{"issue":"8","key":"503_CR9","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1308573","volume":"370","author":"MR Gilbert","year":"2014","unstructured":"Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta MP (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370(8):699\u2013708. https:\/\/doi.org\/10.1056\/NEJMoa1308573","journal-title":"N Engl J Med"},{"issue":"8","key":"503_CR10","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1308345","volume":"370","author":"OL Chinot","year":"2014","unstructured":"Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370(8):709\u2013722. https:\/\/doi.org\/10.1056\/NEJMoa1308345","journal-title":"N Engl J Med"},{"issue":"30","key":"503_CR11","doi-asserted-by":"publisher","first-page":"4601","DOI":"10.1200\/JCO.2009.27.1932","volume":"28","author":"M Brada","year":"2010","unstructured":"Brada M, Stenning S, Gabe R, Thompson LC, Levy D, Rampling R, Erridge S, Saran F, Gattamaneni R, Hopkins K, Beall S, Collins VP, Lee SM (2010) Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. J Clin Oncol 28(30):4601\u20134608. https:\/\/doi.org\/10.1200\/JCO.2009.27.1932","journal-title":"J Clin Oncol"},{"issue":"2","key":"503_CR12","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1200\/JCO.2001.19.2.509","volume":"19","author":"Medical Research Council Brain Tumor Working P","year":"2001","unstructured":"Medical Research Council Brain Tumor Working P (2001) Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J Clin Oncol 19(2):509\u2013518. https:\/\/doi.org\/10.1200\/JCO.2001.19.2.509","journal-title":"J Clin Oncol"},{"key":"503_CR13","doi-asserted-by":"publisher","unstructured":"Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann RD, Pietsch T, Wiestler OD, Ernemann U, Bamberg M, Reifenberger G, von Deimling A, Weller M (2009) NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, https:\/\/doi.org\/10.1200\/JCO.2009.23.6497","DOI":"10.1200\/JCO.2009.23.6497"},{"key":"503_CR14","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jbi.2016.09.019","volume":"64","author":"Y Chen","year":"2016","unstructured":"Chen Y, Xu R (2016) Drug repurposing for glioblastoma based on molecular subtypes. J Biomed Inform 64:131\u2013138. https:\/\/doi.org\/10.1016\/j.jbi.2016.09.019","journal-title":"J Biomed Inform"},{"key":"503_CR15","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3332\/ecancer.2014.485","volume":"8","author":"P Pantziarka","year":"2014","unstructured":"Pantziarka P, Bouche G, Meheus L, Sukhatme V, Sukhatme VP (2014) Repurposing drugs in oncology (ReDO)-mebendazole as an anti-cancer agent. Ecancermedicalscience 8:443. https:\/\/doi.org\/10.3332\/ecancer.2014.443","journal-title":"Ecancermedicalscience"},{"issue":"7","key":"503_CR16","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1200\/JCO.2015.63.6563","volume":"34","author":"C Happold","year":"2016","unstructured":"Happold C, Gorlia T, Chinot O, Gilbert MR, Nabors LB, Wick W, Pugh SL, Hegi M, Cloughesy T, Roth P, Reardon DA, Perry JR, Mehta MP, Stupp R, Weller M (2016) Does Valproic acid or Levetiracetam improve survival in glioblastoma? A pooled analysis of prospective clinical trials in newly diagnosed glioblastoma. J Clin Oncol 34(7):731\u2013739. https:\/\/doi.org\/10.1200\/JCO.2015.63.6563","journal-title":"J Clin Oncol"},{"issue":"3","key":"503_CR17","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/mc.20267","volume":"46","author":"H Sato","year":"2007","unstructured":"Sato H, Senba H, Virgona N, Fukumoto K, Ishida T, Hagiwara H, Negishi E, Ueno K, Yamasaki H, Yano T (2007) Connexin 32 potentiates vinblastine-induced cytotoxicity in renal cell carcinoma cells. Mol Carcinog 46(3):215\u2013224. https:\/\/doi.org\/10.1002\/mc.20267","journal-title":"Mol Carcinog"},{"issue":"12","key":"503_CR18","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1200\/JCO.2011.34.5843","volume":"30","author":"E Bouffet","year":"2012","unstructured":"Bouffet E, Jakacki R, Goldman S, Hargrave D, Hawkins C, Shroff M, Hukin J, Bartels U, Foreman N, Kellie S, Hilden J, Etzl M, Wilson B, Stephens D, Tabori U, Baruchel S (2012) Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma. J Clin Oncol 30(12):1358\u20131363. https:\/\/doi.org\/10.1200\/JCO.2011.34.5843","journal-title":"J Clin Oncol"},{"issue":"15","key":"503_CR19","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.2174\/1568026615666150414120547","volume":"15","author":"CT Lee","year":"2015","unstructured":"Lee CT, Huang YW, Yang CH, Huang KS (2015) Drug delivery systems and combination therapy by using vinca alkaloids. Curr Top Med Chem 15(15):1491\u20131500","journal-title":"Curr Top Med Chem"},{"issue":"2","key":"503_CR20","first-page":"139","volume":"1","author":"DJ Stewart","year":"1983","unstructured":"Stewart DJ, Lu K, Benjamin RS, Leavens ME, Luna M, Yap HY, Loo TL (1983) Concentration of vinblastine in human intracerebral tumor and other tissues. J Neuro-Oncol 1(2):139\u2013144","journal-title":"J Neuro-Oncol"},{"issue":"9","key":"503_CR21","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1093\/neuonc\/nor077","volume":"13","author":"RY Bai","year":"2011","unstructured":"Bai RY, Staedtke V, Aprhys CM, Gallia GL, Riggins GJ (2011) Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme. Neuro-Oncology 13(9):974\u2013982. https:\/\/doi.org\/10.1093\/neuonc\/nor077","journal-title":"Neuro-Oncology"},{"issue":"1\u20132","key":"503_CR22","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.mrgentox.2013.06.010","volume":"756","author":"PR Godoy","year":"2013","unstructured":"Godoy PR, Mello SS, Magalhaes DA, Donaires FS, Nicolucci P, Donadi EA, Passos GA, Sakamoto-Hojo ET (2013) Ionizing radiation-induced gene expression changes in TP53 proficient and deficient glioblastoma cell lines. Mutat Res 756(1\u20132):46\u201355. https:\/\/doi.org\/10.1016\/j.mrgentox.2013.06.010","journal-title":"Mutat Res"},{"issue":"6","key":"503_CR23","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/sj.bjc.6690802","volume":"81","author":"M Brada","year":"1999","unstructured":"Brada M, Judson I, Beale P, Moore S, Reidenberg P, Statkevich P, Dugan M, Batra V, Cutler D (1999) Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer 81(6):1022\u20131030. https:\/\/doi.org\/10.1038\/sj.bjc.6690802","journal-title":"Br J Cancer"},{"issue":"2","key":"503_CR24","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/BF00542462","volume":"22","author":"PA Braithwaite","year":"1982","unstructured":"Braithwaite PA, Roberts MS, Allan RJ, Watson TR (1982) Clinical pharmacokinetics of high dose mebendazole in patients treated for cystic hydatid disease. Eur J Clin Pharmacol 22(2):161\u2013169","journal-title":"Eur J Clin Pharmacol"},{"issue":"10","key":"503_CR25","doi-asserted-by":"publisher","first-page":"13743","DOI":"10.1007\/s13277-016-5255-z","volume":"37","author":"AO Silva","year":"2016","unstructured":"Silva AO, Felipe KB, Villodre ES, Lopez PL, Lenz G (2016) A guide for the analysis of long-term population growth in cancer. Tumour Biol 37(10):13743\u201313749. https:\/\/doi.org\/10.1007\/s13277-016-5255-z","journal-title":"Tumour Biol"},{"issue":"8","key":"503_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0042522","volume":"7","author":"EC Filippi-Chiela","year":"2012","unstructured":"Filippi-Chiela EC, Oliveira MM, Jurkovski B, Callegari-Jacques SM, da Silva VD, Lenz G (2012) Nuclear morphometric analysis (NMA): screening of senescence, apoptosis and nuclear irregularities. PLoS One 7(8):e42522. https:\/\/doi.org\/10.1371\/journal.pone.0042522","journal-title":"PLoS One"},{"issue":"2","key":"503_CR27","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.yexcr.2016.09.014","volume":"348","author":"AO Silva","year":"2016","unstructured":"Silva AO, Dalsin E, Onzi GR, Filippi-Chiela EC, Lenz G (2016) The regrowth kinetic of the surviving population is independent of acute and chronic responses to temozolomide in glioblastoma cell lines. Exp Cell Res 348(2):177\u2013183. https:\/\/doi.org\/10.1016\/j.yexcr.2016.09.014","journal-title":"Exp Cell Res"},{"issue":"11","key":"503_CR28","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.1158\/0008-5472.CAN-12-3902","volume":"73","author":"H Cui","year":"2013","unstructured":"Cui H, Kong Y, Xu M, Zhang H (2013) Notch3 functions as a tumor suppressor by controlling cellular senescence. Cancer Res 73(11):3451\u20133459. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-3902","journal-title":"Cancer Res"},{"issue":"4","key":"503_CR29","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.molmed.2017.02.001","volume":"23","author":"AG Georgakilas","year":"2017","unstructured":"Georgakilas AG, Martin OA, Bonner WM (2017) p21: a two-faced genome Guardian. Trends Mol Med 23(4):310\u2013319. https:\/\/doi.org\/10.1016\/j.molmed.2017.02.001","journal-title":"Trends Mol Med"},{"issue":"3","key":"503_CR30","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s11060-011-0709-z","volume":"106","author":"KE Warren","year":"2012","unstructured":"Warren KE, Gururangan S, Geyer JR, McLendon RE, Poussaint TY, Wallace D, Balis FM, Berg SL, Packer RJ, Goldman S, Minturn JE, Pollack IF, Boyett JM, Kun LE (2012) A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a pediatric brain tumor consortium study. J Neuro-Oncol 106(3):643\u2013649. https:\/\/doi.org\/10.1007\/s11060-011-0709-z","journal-title":"J Neuro-Oncol"},{"issue":"11","key":"503_CR31","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1093\/neuonc\/not104","volume":"15","author":"C Riganti","year":"2013","unstructured":"Riganti C, Salaroglio IC, Caldera V, Campia I, Kopecka J, Mellai M, Annovazzi L, Bosia A, Ghigo D, Schiffer D (2013) Temozolomide downregulates P-glycoprotein expression in glioblastoma stem cells by interfering with the Wnt3a\/glycogen synthase-3 kinase\/beta-catenin pathway. Neuro-Oncology 15(11):1502\u20131517. https:\/\/doi.org\/10.1093\/neuonc\/not104","journal-title":"Neuro-Oncology"},{"issue":"8","key":"503_CR32","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1158\/1541-7786.MCR-07-2159","volume":"6","author":"N Doudican","year":"2008","unstructured":"Doudican N, Rodriguez A, Osman I, Orlow SJ (2008) Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells. Mol Cancer Res 6(8):1308\u20131315. https:\/\/doi.org\/10.1158\/1541-7786.MCR-07-2159","journal-title":"Mol Cancer Res"},{"issue":"2","key":"503_CR33","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/CAD.0b013e32835a43f1","volume":"24","author":"NA Doudican","year":"2013","unstructured":"Doudican NA, Byron SA, Pollock PM, Orlow SJ (2013) XIAP downregulation accompanies mebendazole growth inhibition in melanoma xenografts. Anti-Cancer Drugs 24(2):181\u2013188. https:\/\/doi.org\/10.1097\/CAD.0b013e32835a43f1","journal-title":"Anti-Cancer Drugs"},{"issue":"23","key":"503_CR34","doi-asserted-by":"publisher","first-page":"4824","DOI":"10.1182\/blood-2009-09-243055","volume":"115","author":"PA Spagnuolo","year":"2010","unstructured":"Spagnuolo PA, Hu J, Hurren R, Wang X, Gronda M, Sukhai MA, Di Meo A, Boss J, Ashali I, Beheshti Zavareh R, Fine N, Simpson CD, Sharmeen S, Rottapel R, Schimmer AD (2010) The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma. Blood 115(23):4824\u20134833. https:\/\/doi.org\/10.1182\/blood-2009-09-243055","journal-title":"Blood"},{"issue":"11","key":"503_CR35","first-page":"1231","volume":"4","author":"M Moudi","year":"2013","unstructured":"Moudi M, Go R, Yien CY, Nazre M (2013) Vinca alkaloids. Int J Prev Med 4(11):1231\u20131235","journal-title":"Int J Prev Med"},{"issue":"4","key":"503_CR36","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1215\/S1152851703000516","volume":"6","author":"FM Boyle","year":"2004","unstructured":"Boyle FM, Eller SL, Grossman SA (2004) Penetration of intra-arterially administered vincristine in experimental brain tumor. Neuro-Oncology 6(4):300\u2013305. https:\/\/doi.org\/10.1215\/S1152851703000516","journal-title":"Neuro-Oncology"},{"key":"503_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.489","volume":"5","author":"M Althubiti","year":"2014","unstructured":"Althubiti M, Lezina L, Carrera S, Jukes-Jones R, Giblett SM, Antonov A, Barlev N, Saldanha GS, Pritchard CA, Cain K, Macip S (2014) Characterization of novel markers of senescence and their prognostic potential in cancer. Cell Death Dis 5:e1528. https:\/\/doi.org\/10.1038\/cddis.2014.489","journal-title":"Cell Death Dis"},{"issue":"3","key":"503_CR38","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1080\/15384101.2015.1127474","volume":"15","author":"CF Chen","year":"2016","unstructured":"Chen CF, Dou XW, Liang YK, Lin HY, Bai JW, Zhang XX, Wei XL, Li YC, Zhang GJ (2016) Notch3 overexpression causes arrest of cell cycle progression by inducing Cdh1 expression in human breast cancer cells. Cell Cycle 15(3):432\u2013440. https:\/\/doi.org\/10.1080\/15384101.2015.1127474","journal-title":"Cell Cycle"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-017-0503-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-017-0503-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-017-0503-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T05:14:15Z","timestamp":1678511655000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-017-0503-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,29]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["503"],"URL":"https:\/\/doi.org\/10.1007\/s10637-017-0503-7","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,29]]},"assertion":[{"value":"3 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors indicate no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients participated in clinical studies approved by the Federal University of Rio Grande do Sul and Pontifical Catholic University of Rio Grande do Sul Institutional Review Board. Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}